An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-10

AUTHORS

H. Hirte, D. Stewart, R. Goel, E. Chouinard, S. Huan, S. Stafford, B. Waterfield, S. Matthews, C. Lathia, B. Schwartz, V. Agarwal, R. Humphrey, and L. Seymour

ABSTRACT

BACKGROUND: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin in patients with advanced solid tumours, and to identify the maximum tolerated dose of these agents in combination and the dose for use in subsequent studies. PATIENTS AND METHODS: 14 patients were entered onto 3 dose levels consisting of escalating doses of doxorubicin (50 mg/m(2), 60 mg/m(2) and 70 mg/m(2)) with 800 mg po bid BAY 12-9566. At all three dose levels, patients received doxorubicin alone in cycle one on day 1. Daily oral dosing with BAY 12-9566 was started on day 8 of cycle 1, and thus doxorubicin was given concurrently with BAY 12-9566 in cycle 2. Patients were continued on treatment until a dose limiting toxicity or tumour progression occurred. RESULTS: Pharmacokinetic studies from cycles 1 and 2 from the patients treated in the first three dose levels demonstrated that the addition of BAY 12-9566 increased the AUC(0-12h) levels of doxorubicin by a median of 48%. No effects were seen on the BAY 12-9566 pharmacokinetic values. Two dose limiting toxicities were seen at the third dose level. One patient experienced grade 3 stomatitis in cycle 2, and another patient experienced grade 4 granulocytopenia in cycle 1 and grade 4 thrombocytopenia in cycle 2. Thus the maximum tolerated dose of 60 mg/m(2) was declared. These toxicities were those that would have been expected from doxorubicin alone. CONCLUSIONS: BAY 12-9566 can be safely administered with full doses of doxorubicin without evidence of clinical interaction. The recommended dose of doxorubicin to be combined with BAY 12-9566 800 mg po b.i.d is 60 mg/m(2), however, further development of BAY 12-9566 has been abandoned. More... »

PAGES

437-443

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-005-2903-3

DOI

http://dx.doi.org/10.1007/s10637-005-2903-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050509309

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16133795


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibiotics, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biphenyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organic Chemicals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylbutyrates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Inhibitor of Metalloproteinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hamilton Health Sciences", 
          "id": "https://www.grid.ac/institutes/grid.413615.4", 
          "name": [
            "Hamilton Regional Cancer Centre, Hamilton, Ontario", 
            "Hamilton Regional Cancer Centre, L8V 5C2, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hirte", 
        "givenName": "H.", 
        "id": "sg:person.01372604023.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372604023.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Regional Cancer Foundation", 
          "id": "https://www.grid.ac/institutes/grid.419945.4", 
          "name": [
            "Ottawa Regional Cancer Centre, Ottawa, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stewart", 
        "givenName": "D.", 
        "id": "sg:person.011333707042.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011333707042.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Regional Cancer Foundation", 
          "id": "https://www.grid.ac/institutes/grid.419945.4", 
          "name": [
            "Ottawa Regional Cancer Centre, Ottawa, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goel", 
        "givenName": "R.", 
        "id": "sg:person.0753774255.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753774255.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hamilton Health Sciences", 
          "id": "https://www.grid.ac/institutes/grid.413615.4", 
          "name": [
            "Hamilton Regional Cancer Centre, Hamilton, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chouinard", 
        "givenName": "E.", 
        "id": "sg:person.01176602122.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176602122.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Regional Cancer Foundation", 
          "id": "https://www.grid.ac/institutes/grid.419945.4", 
          "name": [
            "Ottawa Regional Cancer Centre, Ottawa, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huan", 
        "givenName": "S.", 
        "id": "sg:person.01204451255.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204451255.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hamilton Health Sciences", 
          "id": "https://www.grid.ac/institutes/grid.413615.4", 
          "name": [
            "Hamilton Regional Cancer Centre, Hamilton, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stafford", 
        "givenName": "S.", 
        "id": "sg:person.0635537622.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635537622.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Regional Cancer Foundation", 
          "id": "https://www.grid.ac/institutes/grid.419945.4", 
          "name": [
            "Ottawa Regional Cancer Centre, Ottawa, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Waterfield", 
        "givenName": "B.", 
        "id": "sg:person.01034775711.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034775711.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "National Cancer Institute of Canada\u2014Clinical Trials Group, Kingston, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matthews", 
        "givenName": "S.", 
        "id": "sg:person.01067474316.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067474316.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.410314.3", 
          "name": [
            "Bayer Inc., Etobicoke, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lathia", 
        "givenName": "C.", 
        "id": "sg:person.01271606403.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271606403.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.410314.3", 
          "name": [
            "Bayer Inc., Etobicoke, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "B.", 
        "id": "sg:person.0647410014.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647410014.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.410314.3", 
          "name": [
            "Bayer Inc., Etobicoke, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agarwal", 
        "givenName": "V.", 
        "id": "sg:person.0755340376.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755340376.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.410314.3", 
          "name": [
            "Bayer Inc., Etobicoke, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Humphrey", 
        "givenName": "R.", 
        "id": "sg:person.01134330022.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134330022.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "National Cancer Institute of Canada\u2014Clinical Trials Group, Kingston, Ontario"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seymour", 
        "givenName": "and L.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1749-6632.1994.tb24719.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009842687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-6632.1994.tb24722.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021497624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-6632.1994.tb24738.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026946051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00007691-199310000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036698812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00007691-199310000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036698812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049278910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008347630465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/jlc-100101774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058432333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.14.1138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14728214.2.1.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067590122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.1.178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074572228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.bmb.a072968", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082409679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082875154", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a059091", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082936497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.6.2150", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083277783"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-10", 
    "datePublishedReg": "2005-10-01", 
    "description": "BACKGROUND: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin in patients with advanced solid tumours, and to identify the maximum tolerated dose of these agents in combination and the dose for use in subsequent studies.\nPATIENTS AND METHODS: 14 patients were entered onto 3 dose levels consisting of escalating doses of doxorubicin (50 mg/m(2), 60 mg/m(2) and 70 mg/m(2)) with 800 mg po bid BAY 12-9566. At all three dose levels, patients received doxorubicin alone in cycle one on day 1. Daily oral dosing with BAY 12-9566 was started on day 8 of cycle 1, and thus doxorubicin was given concurrently with BAY 12-9566 in cycle 2. Patients were continued on treatment until a dose limiting toxicity or tumour progression occurred.\nRESULTS: Pharmacokinetic studies from cycles 1 and 2 from the patients treated in the first three dose levels demonstrated that the addition of BAY 12-9566 increased the AUC(0-12h) levels of doxorubicin by a median of 48%. No effects were seen on the BAY 12-9566 pharmacokinetic values. Two dose limiting toxicities were seen at the third dose level. One patient experienced grade 3 stomatitis in cycle 2, and another patient experienced grade 4 granulocytopenia in cycle 1 and grade 4 thrombocytopenia in cycle 2. Thus the maximum tolerated dose of 60 mg/m(2) was declared. These toxicities were those that would have been expected from doxorubicin alone.\nCONCLUSIONS: BAY 12-9566 can be safely administered with full doses of doxorubicin without evidence of clinical interaction. The recommended dose of doxorubicin to be combined with BAY 12-9566 800 mg po b.i.d is 60 mg/m(2), however, further development of BAY 12-9566 has been abandoned.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-005-2903-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "name": "An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin", 
    "pagination": "437-443", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f09c48474909c074b8735ab4187ad0d767499ef0389bad672c895831421ea65e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16133795"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-005-2903-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050509309"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-005-2903-3", 
      "https://app.dimensions.ai/details/publication/pub.1050509309"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000359_0000000359/records_29181_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-005-2903-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2903-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2903-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2903-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2903-3'


 

This table displays all metadata directly associated to this object as RDF triples.

263 TRIPLES      21 PREDICATES      58 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-005-2903-3 schema:about N09f3f9a64fdc4731a883ccca40a5c074
2 N30a4003d3e74470aadbed39045e6e9ed
3 N42fce5c5e7684e608a3172829b8dab5e
4 N579b8fdec3d94d159c8f546693e2e5b3
5 N5bfa21c2fba848fbb0248cd8793082a7
6 N71a91454e7cc4349b6892ab87e54a21a
7 N7758160a654440efa86c26897c044114
8 N8ba338dc086649e4ba8c732ae24066e6
9 N9c14bb7d2b0a4e2f8d2e5e6a1122582a
10 Naa82bec855d44818ae0212fa92f0b295
11 Nb5cb267cf4b34737881a316d836cfa17
12 Nccbebdc69c264c59a14746681d5df2e4
13 Nce0e3c797332413e8c120e0653bba0d0
14 Nf5001a395768427e8de9b8861225ea31
15 Nfb81a39b8af948008c6956c5299e056f
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author Ndd67e0028ab348df8f678b0c96548c08
19 schema:citation https://app.dimensions.ai/details/publication/pub.1082875154
20 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
21 https://doi.org/10.1023/a:1008347630465
22 https://doi.org/10.1081/jlc-100101774
23 https://doi.org/10.1093/jnci/85.14.1138
24 https://doi.org/10.1093/oxfordjournals.annonc.a059091
25 https://doi.org/10.1093/oxfordjournals.bmb.a072968
26 https://doi.org/10.1097/00007691-199310000-00016
27 https://doi.org/10.1111/j.1749-6632.1994.tb24719.x
28 https://doi.org/10.1111/j.1749-6632.1994.tb24722.x
29 https://doi.org/10.1111/j.1749-6632.1994.tb24738.x
30 https://doi.org/10.1200/jco.1998.16.6.2150
31 https://doi.org/10.1200/jco.2000.18.1.178
32 https://doi.org/10.1517/14728214.2.1.205
33 schema:datePublished 2005-10
34 schema:datePublishedReg 2005-10-01
35 schema:description BACKGROUND: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin in patients with advanced solid tumours, and to identify the maximum tolerated dose of these agents in combination and the dose for use in subsequent studies. PATIENTS AND METHODS: 14 patients were entered onto 3 dose levels consisting of escalating doses of doxorubicin (50 mg/m(2), 60 mg/m(2) and 70 mg/m(2)) with 800 mg po bid BAY 12-9566. At all three dose levels, patients received doxorubicin alone in cycle one on day 1. Daily oral dosing with BAY 12-9566 was started on day 8 of cycle 1, and thus doxorubicin was given concurrently with BAY 12-9566 in cycle 2. Patients were continued on treatment until a dose limiting toxicity or tumour progression occurred. RESULTS: Pharmacokinetic studies from cycles 1 and 2 from the patients treated in the first three dose levels demonstrated that the addition of BAY 12-9566 increased the AUC(0-12h) levels of doxorubicin by a median of 48%. No effects were seen on the BAY 12-9566 pharmacokinetic values. Two dose limiting toxicities were seen at the third dose level. One patient experienced grade 3 stomatitis in cycle 2, and another patient experienced grade 4 granulocytopenia in cycle 1 and grade 4 thrombocytopenia in cycle 2. Thus the maximum tolerated dose of 60 mg/m(2) was declared. These toxicities were those that would have been expected from doxorubicin alone. CONCLUSIONS: BAY 12-9566 can be safely administered with full doses of doxorubicin without evidence of clinical interaction. The recommended dose of doxorubicin to be combined with BAY 12-9566 800 mg po b.i.d is 60 mg/m(2), however, further development of BAY 12-9566 has been abandoned.
36 schema:genre research_article
37 schema:inLanguage en
38 schema:isAccessibleForFree false
39 schema:isPartOf N8ac7fe1617b34201a8112f12fbee4c26
40 N99c9fae9c73a443a85fcc6aeac515a3e
41 sg:journal.1094201
42 schema:name An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin
43 schema:pagination 437-443
44 schema:productId N0f0d610241994c9ab1ca14708922f053
45 N4487df7eb1374864beff186b3930b66f
46 N45976a0a5a904fe8b9e82e5202d0501b
47 N62fe1cff5e9949e1b6b191dc8a5d7a96
48 N910fd49fde69418781785525d0d425be
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050509309
50 https://doi.org/10.1007/s10637-005-2903-3
51 schema:sdDatePublished 2019-04-11T11:50
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N33d08814c21a47838259fc1394cb923c
54 schema:url https://link.springer.com/10.1007%2Fs10637-005-2903-3
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N09f3f9a64fdc4731a883ccca40a5c074 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Sarcoma
60 rdf:type schema:DefinedTerm
61 N0f0d610241994c9ab1ca14708922f053 schema:name doi
62 schema:value 10.1007/s10637-005-2903-3
63 rdf:type schema:PropertyValue
64 N27599d38ff184b3aa0766954bed5e4ab rdf:first sg:person.01176602122.37
65 rdf:rest Nede899d0241a4e2a810f0e7cc3b2a773
66 N2a011c8e6bac4ad3a07b91bd74f4a198 rdf:first sg:person.01067474316.33
67 rdf:rest N6c8dac98bca0479d857e0d52787d19d0
68 N30a4003d3e74470aadbed39045e6e9ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Antibiotics, Antineoplastic
70 rdf:type schema:DefinedTerm
71 N33d08814c21a47838259fc1394cb923c schema:name Springer Nature - SN SciGraph project
72 rdf:type schema:Organization
73 N42fce5c5e7684e608a3172829b8dab5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Biphenyl Compounds
75 rdf:type schema:DefinedTerm
76 N4487df7eb1374864beff186b3930b66f schema:name pubmed_id
77 schema:value 16133795
78 rdf:type schema:PropertyValue
79 N45976a0a5a904fe8b9e82e5202d0501b schema:name dimensions_id
80 schema:value pub.1050509309
81 rdf:type schema:PropertyValue
82 N540d9f218e554821a05e3325ee872bd6 rdf:first sg:person.011333707042.86
83 rdf:rest Na5eaedf6474847ee92186675a2041548
84 N579b8fdec3d94d159c8f546693e2e5b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Tissue Inhibitor of Metalloproteinases
86 rdf:type schema:DefinedTerm
87 N5ac2bcc488c84fb6a673e49be3ccf1a7 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
88 schema:familyName Seymour
89 schema:givenName and L.
90 rdf:type schema:Person
91 N5bfa21c2fba848fbb0248cd8793082a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Phenylbutyrates
93 rdf:type schema:DefinedTerm
94 N5c5d9c3e8391487a94ba1aa004a9fa74 rdf:first sg:person.0647410014.27
95 rdf:rest N9176f75f5f1a41cebefd6feac9efdaea
96 N62fe1cff5e9949e1b6b191dc8a5d7a96 schema:name nlm_unique_id
97 schema:value 8309330
98 rdf:type schema:PropertyValue
99 N6c8dac98bca0479d857e0d52787d19d0 rdf:first sg:person.01271606403.17
100 rdf:rest N5c5d9c3e8391487a94ba1aa004a9fa74
101 N71a91454e7cc4349b6892ab87e54a21a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Organic Chemicals
103 rdf:type schema:DefinedTerm
104 N7758160a654440efa86c26897c044114 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Area Under Curve
106 rdf:type schema:DefinedTerm
107 N8ac7fe1617b34201a8112f12fbee4c26 schema:volumeNumber 23
108 rdf:type schema:PublicationVolume
109 N8ba338dc086649e4ba8c732ae24066e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Adult
111 rdf:type schema:DefinedTerm
112 N910fd49fde69418781785525d0d425be schema:name readcube_id
113 schema:value f09c48474909c074b8735ab4187ad0d767499ef0389bad672c895831421ea65e
114 rdf:type schema:PropertyValue
115 N9176f75f5f1a41cebefd6feac9efdaea rdf:first sg:person.0755340376.04
116 rdf:rest Ne8d0c948ad4a4705acb368938fd790c0
117 N941a94dcab0042538c0ce81e78f012fd rdf:first N5ac2bcc488c84fb6a673e49be3ccf1a7
118 rdf:rest rdf:nil
119 N99c9fae9c73a443a85fcc6aeac515a3e schema:issueNumber 5
120 rdf:type schema:PublicationIssue
121 N9c14bb7d2b0a4e2f8d2e5e6a1122582a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Male
123 rdf:type schema:DefinedTerm
124 Na5eaedf6474847ee92186675a2041548 rdf:first sg:person.0753774255.88
125 rdf:rest N27599d38ff184b3aa0766954bed5e4ab
126 Naa82bec855d44818ae0212fa92f0b295 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Neoplasms
128 rdf:type schema:DefinedTerm
129 Nb5cb267cf4b34737881a316d836cfa17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Doxorubicin
131 rdf:type schema:DefinedTerm
132 Nbb902a7c666741df8afa15cf89fc3a6b rdf:first sg:person.01034775711.02
133 rdf:rest N2a011c8e6bac4ad3a07b91bd74f4a198
134 Nccbebdc69c264c59a14746681d5df2e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Antineoplastic Combined Chemotherapy Protocols
136 rdf:type schema:DefinedTerm
137 Nce0e3c797332413e8c120e0653bba0d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Female
139 rdf:type schema:DefinedTerm
140 Nce4d5f649ca04fc99734f6758360dee0 rdf:first sg:person.0635537622.95
141 rdf:rest Nbb902a7c666741df8afa15cf89fc3a6b
142 Ndd67e0028ab348df8f678b0c96548c08 rdf:first sg:person.01372604023.41
143 rdf:rest N540d9f218e554821a05e3325ee872bd6
144 Ne8d0c948ad4a4705acb368938fd790c0 rdf:first sg:person.01134330022.14
145 rdf:rest N941a94dcab0042538c0ce81e78f012fd
146 Nede899d0241a4e2a810f0e7cc3b2a773 rdf:first sg:person.01204451255.49
147 rdf:rest Nce4d5f649ca04fc99734f6758360dee0
148 Nf5001a395768427e8de9b8861225ea31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Carcinoma
150 rdf:type schema:DefinedTerm
151 Nfb81a39b8af948008c6956c5299e056f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Humans
153 rdf:type schema:DefinedTerm
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
158 schema:name Clinical Sciences
159 rdf:type schema:DefinedTerm
160 sg:journal.1094201 schema:issn 0167-6997
161 1573-0646
162 schema:name Investigational New Drugs
163 rdf:type schema:Periodical
164 sg:person.01034775711.02 schema:affiliation https://www.grid.ac/institutes/grid.419945.4
165 schema:familyName Waterfield
166 schema:givenName B.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034775711.02
168 rdf:type schema:Person
169 sg:person.01067474316.33 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
170 schema:familyName Matthews
171 schema:givenName S.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067474316.33
173 rdf:type schema:Person
174 sg:person.011333707042.86 schema:affiliation https://www.grid.ac/institutes/grid.419945.4
175 schema:familyName Stewart
176 schema:givenName D.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011333707042.86
178 rdf:type schema:Person
179 sg:person.01134330022.14 schema:affiliation https://www.grid.ac/institutes/grid.410314.3
180 schema:familyName Humphrey
181 schema:givenName R.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134330022.14
183 rdf:type schema:Person
184 sg:person.01176602122.37 schema:affiliation https://www.grid.ac/institutes/grid.413615.4
185 schema:familyName Chouinard
186 schema:givenName E.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176602122.37
188 rdf:type schema:Person
189 sg:person.01204451255.49 schema:affiliation https://www.grid.ac/institutes/grid.419945.4
190 schema:familyName Huan
191 schema:givenName S.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204451255.49
193 rdf:type schema:Person
194 sg:person.01271606403.17 schema:affiliation https://www.grid.ac/institutes/grid.410314.3
195 schema:familyName Lathia
196 schema:givenName C.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271606403.17
198 rdf:type schema:Person
199 sg:person.01372604023.41 schema:affiliation https://www.grid.ac/institutes/grid.413615.4
200 schema:familyName Hirte
201 schema:givenName H.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372604023.41
203 rdf:type schema:Person
204 sg:person.0635537622.95 schema:affiliation https://www.grid.ac/institutes/grid.413615.4
205 schema:familyName Stafford
206 schema:givenName S.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635537622.95
208 rdf:type schema:Person
209 sg:person.0647410014.27 schema:affiliation https://www.grid.ac/institutes/grid.410314.3
210 schema:familyName Schwartz
211 schema:givenName B.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647410014.27
213 rdf:type schema:Person
214 sg:person.0753774255.88 schema:affiliation https://www.grid.ac/institutes/grid.419945.4
215 schema:familyName Goel
216 schema:givenName R.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753774255.88
218 rdf:type schema:Person
219 sg:person.0755340376.04 schema:affiliation https://www.grid.ac/institutes/grid.410314.3
220 schema:familyName Agarwal
221 schema:givenName V.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755340376.04
223 rdf:type schema:Person
224 https://app.dimensions.ai/details/publication/pub.1082875154 schema:CreativeWork
225 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278910
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1023/a:1008347630465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303341
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1081/jlc-100101774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058432333
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/jnci/85.14.1138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818042
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1093/oxfordjournals.annonc.a059091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082936497
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1093/oxfordjournals.bmb.a072968 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082409679
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1097/00007691-199310000-00016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036698812
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1111/j.1749-6632.1994.tb24719.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1009842687
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1111/j.1749-6632.1994.tb24722.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021497624
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1111/j.1749-6632.1994.tb24738.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026946051
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1200/jco.1998.16.6.2150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083277783
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1200/jco.2000.18.1.178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074572228
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1517/14728214.2.1.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067590122
250 rdf:type schema:CreativeWork
251 https://www.grid.ac/institutes/grid.410314.3 schema:alternateName Bayer (Canada)
252 schema:name Bayer Inc., Etobicoke, Ontario
253 rdf:type schema:Organization
254 https://www.grid.ac/institutes/grid.410356.5 schema:alternateName Queen's University
255 schema:name National Cancer Institute of Canada—Clinical Trials Group, Kingston, Ontario
256 rdf:type schema:Organization
257 https://www.grid.ac/institutes/grid.413615.4 schema:alternateName Hamilton Health Sciences
258 schema:name Hamilton Regional Cancer Centre, Hamilton, Ontario
259 Hamilton Regional Cancer Centre, L8V 5C2, Hamilton, Ontario, Canada
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.419945.4 schema:alternateName Ottawa Regional Cancer Foundation
262 schema:name Ottawa Regional Cancer Centre, Ottawa, Ontario
263 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...